Tatva Chintan Pharma Chem Reports Strong Q1 Results with 27.7% Profit Growth 1 day ago Yesterday
Tatva Chintan Pharma Chem Ltd. reported robust Q1 financial results. Revenue from operations increased by 10.8% to ₹1,168.64 crore, while profit after tax surged by 27.7% to ₹66.51 crore. EBITDA expanded by 37.4% to ₹173.30 crore, with operating margins improving to 14.8%. The company saw growth across product categories, particularly in Structure Directing Agents and Pharma & Agrochemical Intermediates segments. The strong performance is attributed to an improved product mix, operational efficiency, and market expansion. With a strong order book and ongoing capacity expansion, Tatva Chintan is positioned for continued growth.
Tatva Chintan Reports Strong Q1 Performance with 11% Revenue Growth 1 day ago
Tatva Chintan Reports Q1 Results, Approves Director Reappointments and CFO Resignation 2 days ago
Tatva Chintan Pharma Chem Surges 14% as Mukul Agrawal Acquires 1.28% Stake 8 days ago
Mukul Mahavir Agrawal Acquires 1.28% Stake in Tatva Chintan Pharma Chem; Company Announces Q1 FY26 Board Meeting 8 days ago
More news about Tatva Chintan Pharma
17Jul 25
Mukul Mahavir Agrawal Acquires 1.28% Stake in Tatva Chintan Pharma Chem; Company Schedules Q1 FY26 Results
Investor Mukul Mahavir Agrawal has acquired a 1.28% stake in Tatva Chintan Pharma Chem Limited during the first quarter. The company's Board of Directors will meet on July 24, 2025, to approve Q1 FY26 financial results, followed by an earnings call featuring key company representatives. The trading window for the company's equity shares will be closed from July 1, 2025, until 48 hours after the Q1 FY26 results are made public.
18Jun 25
CRISIL Downgrades Tatva Chintan Pharma Chem's Ratings Amid Business Challenges
CRISIL has downgraded Tatva Chintan Pharma Chem Ltd's ratings on bank facilities worth ₹245.00 crore. Long-term rating revised from A- (negative) to BBB+ (stable), and short-term rating from A2+ to A2. The downgrade is due to expected revenue decline to ₹385.00 crore and operating profit margin compression to 9.49% from 18.43%.
05May 25
Tatva Chintan Pharma Chem Secures ₹29.95 Crore Export Order for Specialty Chemicals
Tatva Chintan Pharma Chem Limited has received a significant export order worth ₹29.95 crore (USD 3.56 million) for supplying specialty chemicals in the Pharma & Agro Intermediates & Specialty Chemicals (PASC) category. The order, placed by an international client, is set for delivery in November/December 2025. This development is expected to boost the company's revenue for Q3 FY26 and strengthen its position in the global specialty chemicals market.
Tatva Chintan Pharma Chem Ltd. (TCPCL) reported a significant improvement in Q4 FY2024-25 financials. Net profit rose to ₹10.30 crore from ₹1.38 crore in Q3, though down from ₹96.00 crore year-over-year. Revenue increased by 5.64% YoY to ₹108.60 crore. The company showed substantial QoQ improvements in revenue (26.43% increase) and EBITDA (36.62% increase). Despite YoY challenges, TCPCL demonstrated resilience with improved quarterly performance. A final dividend of ₹1.00 per equity share was recommended.
Tatva Chintan Pharma Chem Limited reported mixed financial results for Q4 and FY 2024-25. Q4 revenue increased 9.80% YoY to ₹1,078.64 crore, but net profit fell to ₹10.30 crore from ₹96.14 crore. FY25 saw a marginal decrease in annual revenue to ₹3,827.14 crore, with net profit declining 68.30% to ₹96.14 crore. Despite challenges, a final dividend of ₹1 per share was recommended. The company faces profitability pressures but shows resilience in revenue growth amid sector headwinds.